Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Prostate Cancer Diagnosis, Localisation and Characterisation using Ultrasound

Project description

Modern ultrasound imaging for comprehensive prostate cancer diagnostics

Currently, the prostate cancer (PC) diagnostic requires multiple invasive and painful biopsy procedures with a significant risk of adverse health events. Magnetic resonance imaging (MRI) represents an additional PC diagnostic tool but its accessibility to patients is poor. Angiogenesis Analytics in the Netherlands has developed a novel PC imaging diagnostic method based on modern ultrasound imaging technology and innovative signal processing algorithms. The developed solution is less expensive than MRI, does not require the training of specialised radiologists, and will be accessible to patients, thereby improving PC management and reducing healthcare costs. The EU-funded PCAVISION project will complete, validate, and certify the solution, enabling its delivery to 16 EU clinics for long-term demonstration and testing.

Objective

Prostate cancer (PCa), is a type of cancer with the highest incidence (19%) and second mortality rate (8%) in western men. In 2018 in Europe, 140,000 male patients were newly diagnosed with PCa and over 100,000 patients have died from Prostate cancer. Numbers are rising due to the ageing EU population.

The present medical diagnosis procedures are largely based on the execution of multi-biopsy procedure(s) on the patient. Each multi-biopsy procedure is invasive, painful for the patient and incurs significant risk (10%-20%) of adverse health events such as sepsis (8%). Screening programs - comparable to breast cancer screening for woman - are not possible based on biopsy.

In recent years, in a few EU countries, an image-based diagnosis method has been added to the PCa diagnosis pathway: Magnetic Resonance Imaging (MRI). A dedicated MRI imaging protocol offers an additional diagnosis tool for detecting and characterising PCa tumour growth.

However, MRI based PCa diagnosis has drawbacks: scarce patient access (no public healthcare coverage in multiple EU countries) and long waiting times of 35 days median, increased national healthcare cost and dependent on availability of highly trained radiologist. The gap between the need for image based diagnosis and the availability is rapidly widening.

PCaVision is a novel PCa imaging diagnostic method relying on modern ultrasound imaging equipment and advanced signal processing algorithms. Advantages are: equipment costs 96% less and there is not need for a specialised radiologist; the urologist performs the diagnosis. Hence PCaVision makes broad scale access for patients possible, improves PCa healthcare and reduces national healthcare cost.
With PCaVision the gap can be closed for the benefit of all EU patients.

The result of the Transition project is to complete, validate, and certify the PCaVision solution enabling roll-out to 16 EU clinics for clinical long-term demonstration enabling future broad utilisation.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2021-TRANSITIONOPEN-01

See all projects funded under this call

Coordinator

ANGIOGENESIS ANALYTICS BV
Net EU contribution
€ 1 950 000,00
Address
SINT JANSSINGEL 92
5211 DA S-HERTOGENBOSCH
Netherlands
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 4 790 500,00